About us

Pure Biologics is a biopharmaceutical company focused on the biological drug and non-systemic therapies discovery and development. We operate in the areas of immuno-oncology, autoimmunology, and rare neurological diseases, conducting research based on our own technology platforms for the selection of active molecules – antibodies and aptamers.

Pure Biologics also offers commercial partnership options  in several areas including early phase biological drug discovery and development, selection and characterization of antibodies and aptamers, as well as protein production, purification and analysis.

Harnessing the power of antibodies and aptamers
Play movie

Pure Biologics has been operating on the market since 2010. Its headquarters and laboratories are located in Wrocław, Poland. Main areas of activity include biotechnology, biological drug discovery and modern therapeutic solutions based on antibodies and aptamers. Employing almost 100 people, and with a broad portfolio, Pure Biologics is one of Poland’s largest biotechnology companies.

Due to its highly experienced research staff, cutting-edge infrastructure and business acumen, the Company conducts all phases of drug development – from target selection and validation to preclinical studies – on its own.

Additionally, by specializing in the selection of aptamers and antibodies, and in the biophysical analysis of molecular interactions, and the production and analysis of recombinant proteins, Pure Biologics is engaging into partnership with pharmaceutical and biotechnological companies, as well as research institutes all over the world.

Specialists
0
Specialists
R&D projects
0
R&D projects
Molecules screened
0
Molecules screened

Pure Biologics’ therapeutic portfolio includes new immunooncology therapies and non-systemic treatment of autoimmune, neurodegenerative and rare diseases. It is a total of a dozen projects, including five key projects in which we use antibody and aptamer technologies to develop molecules with therapeutic potential.

Pure Biologics engages in commercial collaboration, offering contract research covering three main specialties – aptamers, antibodies and proteins. Our solutions combine a team of highly qualified scientists, the potential of our technology platforms and many years of operational experience.

Pure Biologics comprises a team of extremely talented and energetic people who pursue their goals with passion. Our team consists of employees with broad competences and extensive experience gained in research units from around the world.

History

2010
Pure Biologics incorporation
2011
first business partners in the area of recombinant proteins
2012
headquarters and laboratories moved to Wroclaw Technology Park
2013
start of internal R&D activities
2013
first R&D projects with Polish and foreign grants
2014
transformation into Limited Liability Corporation
2015
first patent application in the field of aptamers
2016
start of internal research on the development of biologically active molecules – antibody and aptamer selection
2017
PB001 and PB002 projects receive funding
2017
Pure Biologics becomes a member of the Horizon2020 project consortium
2018
transformation into a joint-stock company and entering the NewConnect market of the Warsaw Stock Exchange
2019
PB003, PB004, PB005 and PB006 projects receive funding
2020
aptamer patent granted for the USA
2020
entering the main market of the Warsaw Stock Exchange
Menu Close

We use cookies to give you the best browsing experience, site traffic analysis, and advertisement management.